Dr. Reddy's Laboratories reported a 36% decline in quarterly net profit to ₹925 crore, impacted by a ₹239 crore provision for Semaglutide API inventory. Revenue also dipped 1.5% to ₹8,671 crore for the September quarter. Investors are now assessing whether this inventory write-down is a one-time technical adjustment or if it indicates broader challenges in managing production and demand for the company’s specialty drug portfolio.
Dr. Reddy’s Laboratories reported a 36% decline in net profit for the second quarter ended September 2026, with the bottom line settling at ₹925 crore. The company’s revenue also saw a contraction, falling by 1.5% to ₹8,671 crore compared to the same period last year. The primary factor behind this earnings miss was a one-time charge of ₹239 crore related to the inventory of Semaglutide, an active pharmaceutical ingredient (API) used in certain diabetes and weight-loss medications.
The provision significantly impacted the company's operating results for the quarter. In the pharmaceutical manufacturing business, holding the correct amount of inventory for high-demand, complex molecules is a difficult balancing act. A provision of this size suggests that the value of the Semaglutide stock held by the company had to be adjusted downwards. This usually happens due to factors such as excess production, changes in the market price of the raw material, or shifts in the quality and regulatory requirements for that specific batch. While such provisions are often treated as one-time technical adjustments, they directly reduce the profit the company can report for the period.
The decline in revenue, while modest, highlights a challenging environment for the Hyderabad-based manufacturer. Dr. Reddy’s is a prominent player in the global generics market, and its ability to scale production and maintain efficient inventory levels is critical for success in specialized product categories. A write-down of this magnitude raises questions among investors about the company’s inventory management processes, especially as it attempts to tap into the high-growth global market for GLP-1 weight-loss and diabetes drugs.
Looking ahead, the pharmaceutical sector remains highly competitive, with companies constantly balancing the risk of holding too much inventory against the risk of missing out on supply opportunities. For Dr. Reddy’s, the next few quarters will be important for understanding whether this inventory issue was isolated to a specific product batch or if it reflects wider market pressure. Investors and analysts will likely look for management commentary regarding the specific reasons for this write-down, the expected demand for Semaglutide products in the coming months, and whether similar inventory adjustments might be necessary in other parts of the portfolio. Monitoring the company’s operating margins and inventory turnover ratios will provide a clearer picture of whether it can navigate these operational challenges and return to steady growth.